Acrux Limited Reports Earnings Results for the Half Year Ended December 31, 2022

Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto(estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.